Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M A Tempero

Showing results (31-40 of 52) with videos related to

Pageof 6
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1990
Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effectsM A Tempero, C Sivinski, Z Steplewski, et al.
JAMA|September 17, 1982
Detection of metastatic liver disease. Use of liver scans and biochemical liver testsM A Tempero, R J Petersen, R K Zetterman, et al.
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|January 1, 1991
Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinomaM A Tempero, Y Haga, C Sivinski, et al.
Cancer Research|October 15, 1987
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancerM A Tempero, E Uchida, H Takasaki, et al.
Biological Trace Element Research|November 23, 2013
Serum and hair selenium levels in hereditary nonpolyposis colorectal cancerM A Tempero, M M Jacobs, H T Lynch, et al.
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|October 1, 1987
Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissueH Takasaki, E Uchida, M A Tempero, et al.
Cancer Research|March 15, 1988
Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patientsH Takasaki, E Uchida, M A Tempero, et al.
JAMA|November 8, 1985
The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysisA R Berg, J Linder, R W Anderson, et al.
British Journal of Cancer|July 7, 2005
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancerA H Ko, J Hwang, A P Venook, et al.
Cancer Research|June 19, 2001
A white paper: the product of a pancreas cancer think tankS Kern, R Hruban, M A Hollingsworth, et al.
Pageof 6

Showing results (31-40 of 52) with videos related to

Sort By:
Pageof 6
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 1, 1990
Phase II trial of interferon gamma and monoclonal antibody 17-1A in pancreatic cancer: biologic and clinical effectsM A Tempero, C Sivinski, Z Steplewski, et al.
JAMA|September 17, 1982
Detection of metastatic liver disease. Use of liver scans and biochemical liver testsM A Tempero, R J Petersen, R K Zetterman, et al.
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|January 1, 1991
Immunotherapy with monoclonal antibody (Mab) in pancreatic adenocarcinomaM A Tempero, Y Haga, C Sivinski, et al.
Cancer Research|October 15, 1987
Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancerM A Tempero, E Uchida, H Takasaki, et al.
Biological Trace Element Research|November 23, 2013
Serum and hair selenium levels in hereditary nonpolyposis colorectal cancerM A Tempero, M M Jacobs, H T Lynch, et al.
International Journal of Pancreatology : Official Journal of the International Association of Pancreatology|October 1, 1987
Comparative studies on expression of CA 19-9 and DU-PAN-2 in pancreatic cancer tissueH Takasaki, E Uchida, M A Tempero, et al.
Cancer Research|March 15, 1988
Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patientsH Takasaki, E Uchida, M A Tempero, et al.
JAMA|November 8, 1985
The undifferentiated malignant neoplasm. Identification of lymphoma arising in skeletal muscle by immunohistochemical analysisA R Berg, J Linder, R W Anderson, et al.
British Journal of Cancer|July 7, 2005
Serum CA19-9 response as a surrogate for clinical outcome in patients receiving fixed-dose rate gemcitabine for advanced pancreatic cancerA H Ko, J Hwang, A P Venook, et al.
Cancer Research|June 19, 2001
A white paper: the product of a pancreas cancer think tankS Kern, R Hruban, M A Hollingsworth, et al.
Pageof 6